G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor

Summary

The purpose of this study is to explore the effect of G-CSF combination with GM-CSF on prevention and treatment of infection in children with malignant tumor.

Conditions

• Acute Myeloid Leukemia
• Acute Lymphoid Leukemia
• Lymphoma
• Neuroblastoma
• Hepatoblastoma
• Retinoblastoma

Interventions

BIOLOGICAL

GM-CSF

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. GM-CSF is a stimulator of the growth and differentiation of hematopoietic progenitor cells committed to neutrophils, monocytes or eosinophils.

BIOLOGICAL

G-CSF

Granulocyte colony-stimulating factor (G-CSF) is a hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. G-CSF is a relatively specific stimulator of the growth and differentiation of hematopoietic progenitor cells committed to the neutrophil lineage.

BIOLOGICAL

GM-CSF and G-CSF

Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) are hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. GM-CSF and G-CSF share a number of biologic activities, GM-CSF seems to be more potent against fungi.

Sponsors & Collaborators

• Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

  lead OTHER

Principal Investigators

• Yuan Xiaojun, Ph.D · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

• Zhai Xiaowen, Ph.D · Children's Hospital of Fudan University

• Hu Shaoyan, Ph.D · Children's Hospital of Soochow University

• Fang Yongjun, Ph.D · Nanjing Children's Hospital

• Wen Hong, Ph.D · The First Affiliated of Xiamen University

• Wang Hongmei, Ph.D · Qianfoshan Hospital

• Sun Lirong, Ph.D · The Affiliated Hospital of Qingdao University

• Li Aimin, Ph.D · Yantai Yuhuangding Hospital

• Gao Fei, Ph.D · Shandong Proincial Hospital

• Liu Wei, Ph.D · Zhengzhou Children's Hospital

• Liang Changda, Master · Jiangxi Proincial Children's Hospital

• Pan Kaili, Master · Northwest Women's Hospital

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

1 Year

Max Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2016-09-27

Primary Completion

2020-08-30

Completion

2020-12-31

Countries

• China

Study Locations